Concert Pharma GAAP EPS of -$0.58 beats by $0.01, revenue of $0.08M in-line
- Concert Pharma press release (NASDAQ:CNCE): Q3 GAAP EPS of -$0.58 beats by $0.01.
- Revenue of $0.08M (-84.0% Y/Y) in-line.
- Cash, cash equivalents and investments as of September 30, 2022 totaled $148.9 million, compared to $141.6 million as of December 31, 2021. Under its current operating plan, the Company expects its cash, cash equivalents and investments to fund the Company through the second quarter of 2023.